Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates
12 mars 2019 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
●Pipeline of rationally-designed synthetic cannabinoids position Corbus to become the leader in treating inflammatory and fibrotic diseases by targeting the endocannabinoid system (ECS)...
Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
11 mars 2019 08h35 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET- Norwood, MA, March 11, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
Corbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
07 mars 2019 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Tuesday, March 12 at 8:30 a.m. ET - Norwood, MA, March 07, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
04 mars 2019 09h15 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Advances commercialization strategy for lenabasum ahead of data readouts of key registrational studies in 2020, and potential U.S. Food and Drug Administration (“FDA”) approval and launch in 2021Mr....
Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
25 janv. 2019 09h01 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Jan. 25, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company), a clinical stage drug development company with the industry’s leading...
Corbus Pharmaceuticals Announces Issuance of Composition of Matter Patent Related to Lenabasum
18 déc. 2018 08h46 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemLenabasum in late-stage clinical studies in three orphan...
Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis
17 déc. 2018 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30% This marks Company’s second Phase 3 program in rare...
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
22 oct. 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Lenabasum is a first-in-class novel, synthetic oral cannabinoid designed to treat rare, serious autoimmune diseasesFavorable safety and tolerability profiles maintained with long-term chronic...
Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
18 oct. 2018 16h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Study demonstrates that lenabasum decreases inflammatory biomarkers and increases pro-resolving mediators in airway macrophages from cystic fibrosis patientsCystic fibrosis is a life-threatening...
Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union
18 sept. 2018 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as...